Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.36, missing the estimate of USD -0.3372.

EBIT: As of FY2026 Q2, the actual value is USD -22.37 M.

Second Quarter 2026 Financial Results

Operating Expenses

• Research and development expenses decreased to - $16.7 million for the three months ended June 30, 2026, compared to - $32.2 million for the prior-year quarter.
• General and administrative expenses decreased to - $7.1 million for the three months ended June 30, 2026, compared to - $13.4 million for the prior-year quarter.
• Total operating expenses for the three months ended June 30, 2026, were - $23.862 million, down from - $45.592 million in the prior-year quarter.

Net Loss

• Net loss was - $22.4 million for the three months ended June 30, 2026, a decrease from - $43.3 million in the prior-year quarter.
• Net loss per share - basic and diluted was - $0.36 for the three months ended June 30, 2026, compared to - $0.71 for the prior-year quarter.

Six Months Ended June 30, 2026 Financial Results

Operating Expenses

• Research and development expenses were - $30.311 million for the six months ended June 30, 2026, compared to - $75.634 million for the same period in 2025.
• General and administrative expenses were - $15.323 million for the six months ended June 30, 2026, compared to - $28.893 million for the same period in 2025.
• Total operating expenses were - $45.634 million for the six months ended June 30, 2026, compared to - $104.527 million for the same period in 2025.
• Loss from operations was - $45.634 million for the six months ended June 30, 2026, compared to - $104.527 million for the same period in 2025.

Other Income and Expenses

• Interest and other income (expense), net was $3.223 million for the six months ended June 30, 2026, compared to $6.669 million for the same period in 2025.
• Interest expense was $0 for the six months ended June 30, 2026, compared to - $1.608 million for the same period in 2025.

Net Loss

• Net loss was - $42.411 million for the six months ended June 30, 2026, compared to - $99.466 million for the same period in 2025.
• Net loss per share - basic and diluted was - $0.69 for the six months ended June 30, 2026, compared to - $1.62 for the same period in 2025.

Balance Sheet Highlights (as of June 30, 2026)

Cash and Investments

• Cash, cash equivalents and short-term investments totaled $159.6 million as of June 30, 2026.
• Cash and cash equivalents were $24.883 million as of June 30, 2026, down from $45.445 million as of December 31, 2025.
• Short-term investments were $133.218 million as of June 30, 2026, down from $145.499 million as of December 31, 2025.

Assets

• Total current assets were $163.142 million as of June 30, 2026, compared to $196.448 million as of December 31, 2025.
• Total assets were $189.881 million as of June 30, 2026, compared to $225.228 million as of December 31, 2025.

Liabilities

• Accounts payable increased to $1.531 million as of June 30, 2026, from $0.480 million as of December 31, 2025.
• Accrued research and development increased to $9.028 million as of June 30, 2026, from $4.804 million as of December 31, 2025.
• Accrued liabilities decreased to $3.653 million as of June 30, 2026, from $9.634 million as of December 31, 2025.
• Total current liabilities were $16.484 million as of June 30, 2026, compared to $16.365 million as of December 31, 2025.
• Total liabilities were $42.955 million as of June 30, 2026, compared to $44.023 million as of December 31, 2025.

Stockholders’ Equity

• Total stockholders’ equity was $146.926 million as of June 30, 2026, compared to $181.205 million as of December 31, 2025.
• Accumulated deficit was - $901.807 million as of June 30, 2026, compared to - $859.396 million as of December 31, 2025.

Operational Metrics and Outlook

Oncology Program

• Enrollment in the FORTIFY Phase 1b indication expansion trial for PLN-101095 is strong and progressing ahead of schedule, with interim data expected in 2027.
• Updated PLN-101095 Phase 1 monotherapy biomarker data highlighted a coordinated T-cell reactivation cascade in responders.

Integrin-Targeted Delivery Platform

• Pliant Therapeutics, Inc. is advancing a platform to deliver drug payloads, such as siRNAs, to selective tissue types, with preclinical proof-of-concept studies currently ongoing.
• The company plans to provide additional details on this platform, including initial treatment indications, in the second half of 2026.

Corporate Highlights

• Pliant Therapeutics, Inc. appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors, bringing extensive oncology drug development and commercialization expertise.

Outlook

• Pliant Therapeutics, Inc. expects its cash, cash equivalents, and short-term investments of $159.6 million as of June 30, 2026, to be sufficient to fund operations into the second half of 2028.
• The company anticipates sharing more information on its proprietary integrin-targeted drug-delivery platform and its path forward, including initial treatment indications, in the second half of 2026.